Clinical Trials Logo

HER2-positive Gastric Cancer clinical trials

View clinical trials related to HER2-positive Gastric Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05091528 Terminated - Clinical trials for HER2-positive Breast Cancer

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Start date: February 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to assess the safety and preliminary activity of SBT6050 in combination with trastuzumab deruxtecan (Part 1) or tucatinib plus trastuzumab +/- capecitabine (Part 2). Participants will be enrolled into each Arm based on cancer diagnosis and prior therapies.

NCT ID: NCT04727151 Terminated - Clinical trials for HER2 Positive Gastric Cancer

TAC T-cells for the Treatment of HER2-positive Solid Tumors

TACTIC-2
Start date: April 19, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2). TAC directs T-cells to the targeted antigen (HER2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase 1/2 study that aims to establish safety, maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-HER2 as a monotherapy, and in combination with pembrolizumab, in subjects with HER2 positive gastric and gastroesophageal adenocarcinoma.